In-depth coverage of the clinical trials shaping GLP-1, GLP-3, and incretin research — SURMOUNT, SURPASS, STEP, SELECT, and the retatrutide TRIUMPH program. Every quantitative figure is attributed to the named trial or its peer-reviewed publication. Retatrutide and other investigational compounds are not FDA-approved.
A site coordinator is screening a 52-year-old candidate for a Phase 3 multi-receptor agonist trial. BMI is 29.6 — just under the protocol's 30 kg/m2 threshold. Fasting glucose is borderline…
A site coordinator running a phase 2 metabolic trial pulls the enrollment tracker on a Friday afternoon: 260 candidates pre-screened over eight weeks, 91 consented to formal screening, and only 54…
A mid-size CRO running a Phase 2 obesity trial for a triple-receptor peptide submitted its protocol to the FDA with a four-week dose-titration schedule compressed from the sponsor's original…
A trial coordinator running enrollment for a mid-size Phase 3 obesity study once described the problem bluntly: of the first 400 screening calls, fewer than 60 produced eligible participants who…
A site coordinator running enrollment for a Phase 2 GLP-1/GLP-3-class dual-agonist trial watched a full week of screened candidates stall at the same point: the consent form. The central IRB had…
A CRO project manager running a 400-patient phase 2 triple-agonist obesity trial watched the screening log for eleven weeks before flagging the problem to the sponsor: 61% of self-referred…
When the Outcome Measure Doesn't Match the Compound A mid-size CRO running a Phase 1b extension for a multi-receptor peptide agonist recently hit a design wall that has become increasingly common…
The Trial Design Problem Emerging With Triple-Hormone-Receptor AgonistsA phase 2 site coordinator running an obesity trial for a next-generation incretin compound opens enrollment expecting the…
Navigating Informed Consent in GLP-3 Clinical TrialsAs a researcher, ensuring informed consent is a critical component of any clinical trial. The GLP-3 trial I led for my fitness business last…
A hepatology clinic reviewing a stack of transient elastography reports this month will find a familiar pattern: F2-F3 fibrosis on biopsy or imaging, elevated liver enzymes, a patient already on…
When the STEP 1 trial (NCT03548935) reported a 14.9% mean body weight reduction with once-weekly subcutaneous semaglutide 2.4 mg at 68 weeks, that figure became a benchmark for GLP-1 obesity…
What the 48-week Phase 2 data on retatrutide reported for weight and glycemic endpoints, with every figure attributed to the published trial. Retatrutide is investigational and not FDA-approved.
When Weight Loss Becomes a Sleep Apnea Treatment Picture a 54-year-old patient — moderately obese, CPAP-dependent for six years, compliance at maybe 60% on a good month. He shows up to a weight…
A Problem That Weight Loss Alone Wasn't Solving Picture a 54-year-old male patient — 118 kg, BMI 38, moderate-to-severe obstructive sleep apnea confirmed by polysomnography. He's been on CPAP for…
Why the Retatrutide Phase 3 Readout Is the Most-Watched Trial in Metabolic Medicine Right Now Imagine running a weight management clinic. Your best patients on semaglutide 2.4 mg hit a wall at…